Policy | July 23, 2024
Industry hails Union Budget 2024-25
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Establishing Asymchem’s first manufacturing footprint in Europe
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Women emerge as the cornerstone of this monumental undertaking
The investment will catalyse various components of the IndiaAI Mission
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Development services for gene and cell therapies is planned to begin first in 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
